# C_2021029EN.01000401.xml

| 26.1.2021 | EN | Official Journal of the European Union | C 29/4 |
| --- | --- | --- | --- |

26.1.2021

EN

Official Journal of the European Union

C 29/4

---

Prior notification of a concentration

(Case M.10004 - EQT/Zentricity/Cajelo/Recipharm)

Candidate case for simplified procedure

(Text with EEA relevance)

(2021/C 29/04)

1.

This notification concerns the following undertakings:

| — | EQT IX Collect EUR SCSp and EQT IX Collect USD SCSp (together ‘EQT IX’), part of the EQT group of private equity funds (‘EQT’, Luxembourg); |
| --- | --- |

—

EQT IX Collect EUR SCSp and EQT IX Collect USD SCSp (together ‘EQT IX’), part of the EQT group of private equity funds (‘EQT’, Luxembourg);

| — | Zentricity Holding AB (‘Zentricity’, Sweden); |
| --- | --- |

—

Zentricity Holding AB (‘Zentricity’, Sweden);

| — | Cajelo Invest Ltd (‘Cajelo’, Cyprus); and |
| --- | --- |

—

Cajelo Invest Ltd (‘Cajelo’, Cyprus); and

| — | Recipharm AB (‘Recipharm’, Sweden). |
| --- | --- |

—

Recipharm AB (‘Recipharm’, Sweden).

EQT, Zentricity and Cajelo acquire within the meaning of Article 3(1)(b) of the Merger Regulation joint control of the whole of Recipharm.

The concentration is accomplished by way of public bid announced on 14 December 2020.

2.

| — | for EQT: private equity funds that invest in companies across the world, which amongst others control EQT IX, an investment fund investing primarily in Europe, with a focus on Northern Europe; |
| --- | --- |

—

for EQT: private equity funds that invest in companies across the world, which amongst others control EQT IX, an investment fund investing primarily in Europe, with a focus on Northern Europe;

| — | for Zentricity: investment company focusing on investing in pharmaceutical companies primarily in Sweden, which is controlled by private individual Thomas Eldered, who also controls the pharmaceutical companies Empros Pharma AB, Flerie Creations Ltd. and Flerie Invest AB; |
| --- | --- |

—

for Zentricity: investment company focusing on investing in pharmaceutical companies primarily in Sweden, which is controlled by private individual Thomas Eldered, who also controls the pharmaceutical companies Empros Pharma AB, Flerie Creations Ltd. and Flerie Invest AB;

| — | for Cajelo: investment company which is controlled by private individual Lars Backsell, who also controls Glims Marketing Ltd. and Rohirrim AB, a horse breeding company. |
| --- | --- |

—

for Cajelo: investment company which is controlled by private individual Lars Backsell, who also controls Glims Marketing Ltd. and Rohirrim AB, a horse breeding company.

| — | for Recipharm: contract development and manufacturing organization, providing drug development and manufacturing services globally to the pharmaceutical industry (e.g. for finished dose pharmaceuticals, active pharmaceutical ingredients and clinical trial materials for customers in the pharmaceutical industry), as well as packaging services and logistics services. |
| --- | --- |

—

for Recipharm: contract development and manufacturing organization, providing drug development and manufacturing services globally to the pharmaceutical industry (e.g. for finished dose pharmaceuticals, active pharmaceutical ingredients and clinical trial materials for customers in the pharmaceutical industry), as well as packaging services and logistics services.

3.

Pursuant to the Commission Notice on a simplified procedure for treatment of certain concentrations under the Council Regulation (EC) No 139/2004 (2) it should be noted that this case is a candidate for treatment under the procedure set out in the Notice.

4.

Observations must reach the Commission not later than 10 days following the date of this publication. The following reference should always be specified:

M.10004 – EQT/Zentricity/Cajelo/Recipharm

Observations can be sent to the Commission by email, by fax, or by post. Please use the contact details below:

Email: COMP-MERGER-REGISTRY@ec.europa.eu

Fax +32 22964301

Postal address:

| European Commission |
| --- |
| Directorate-General for Competition |
| Merger Registry |
| 1049 Bruxelles/Brussel |
| BELGIQUE/BELGIË |

European Commission

Directorate-General for Competition

Merger Registry

1049 Bruxelles/Brussel

BELGIQUE/BELGIË

---

(1)  OJ L 24, 29.1.2004, p. 1 (the ‘Merger Regulation’).

1

(2)  OJ C 366, 14.12.2013, p. 5.

2

---